Loading...

XLO XILIO THERAPEUTICS INC Expansion Plans 8-K Filing

XL T

XL

XILIO THERAPEUTICS INC

(XLO)

2025 8-K

Stock Option Update

Financial Results Announced

New Clinical Data

Stock Listing Change

Clinical Trial Update

NASDAQ Compliance Issue

Financial Results

Equity Offerings

Product Expansion

Financial Statements

Financial Results

Collaboration Agreement

Investor Update

Stock Sale Agreement

Q3 2024 Results

Financial Results Announcement

Annual Meeting Results

Board Expansion and Directo...

Financial Results Announcement

Financial Results Announcement

Stock Purchase Agreement wi...

License Agreement with Gilead

Equity Awards Granted to Ex...

Phase 1 Clinical Trial Data...

Financial Results Announcement

Financial Results and Inves...

Appointment of Chief Operat...

Annual Meeting of Stockholders

Presentation and Clinical T...

Financial Results Announcement

Appointment of Principal Fi...

Financial Results Announcement

Investor Conferences

External Links:

On May 31, 2025, Xilio Therapeutics, Inc. announced updated data from its Phase 2 trial for vilastobart combined with atezolizumab for colorectal cancer during the ASCO Annual Meeting. A corporate investor presentation is also available on their website.

AI Assistant

XILIO THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.